Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) issued its earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03), Zacks reports. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. The firm had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million.

Aclaris Therapeutics Price Performance

ACRS stock opened at $2.45 on Friday. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $5.61. The business has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $1.24.

Analysts Set New Price Targets

ACRS has been the topic of a number of research analyst reports. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.